


REVIEW ARTICLE

The effect of L-arginine supplementation on maximal oxygen uptake: A systematic review and meta-analysis

Shahla Rezaei^{1,2} | Maryam Gholamalizadeh³ | Reza Tabrizi⁴ | Peyman Nowrouzi-Sohrabi⁵ | Samira Rastgoo⁶ | Saeid Doaei³ 

¹Student Research Committee, Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

²Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

³Student Research Committee, Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁴Non-Communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran

⁵Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

⁶Department of Clinical Nutrition and Dietetics, National Nutrition and Food Technology Research Institute Shahid Beheshti University of Medical Science, Tehran, Iran

Correspondence

Saeid Doaei, Student Research Committee, Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Email: sdoae@yahoo.com

Funding information

Funding for this study was provided by the student research committee of Shahid Beheshti University of Medical Sciences, Tehran, Iran (code: 13172).

Abstract

Background: The efficacy and safety of L-arginine supplements and their effect on maximal oxygen uptake (VO₂ max) remained unclear. This systematic review aimed to investigate the effect of L-arginine supplementation (LAS) on VO₂ max in healthy people.

Methods: We searched PubMed, Scopus, Web of Science, Cochrane, Embase, ProQuest, and Ovid to identify all relevant literature investigating the effect of LAS on VO₂ max. This meta-analysis was conducted via a random-effects model for the best estimation of desired outcomes and studies that meet the inclusion criteria were considered for the final analysis.

Results: The results of 11 randomized clinical trials indicated that LAS increased VO₂ max compared to the control group. There was no significant heterogeneity in this meta-analysis. Subgroup analysis detected that arginine in the form of LAS significantly increased VO₂ max compared to the other forms (weighted mean difference = 0.11 L min⁻¹, $I^2 = 0.0%$, p for heterogeneity = 0.485).

Conclusions: This meta-analysis indicated that supplementation with L-arginine could increase VO₂ max in healthy people. Further studies are warranted to confirm this finding and to identify the underlying mechanisms.

KEYWORDS

L-arginine, maximal oxygen uptake, meta-analysis, VO₂ max

1 | INTRODUCTION

Cardiovascular endurance is one of the most important measures of overall health (Ruiz et al., 2006). A person's level of cardiovascular endurance helps predict ability to react to acute physical and mental stress (Gutin et al., 2005). For healthy individuals, higher cardiovascular endurance also can indicate an elevated level of physical fitness (Haghshenas et al., 2019). One of the best indicators for the athlete's cardiovascular performance is the maximal oxygen uptake (VO₂ max) assessment (Campbell et al., 2006). A greater amount of oxygen consumed by the body is related to higher cardiovascular efficiency (Adams et al., 1995). Higher cardiovascular efficiency allows muscle to work at a higher intensity for a longer time period. The body can only exercise as long as oxygen is delivered to the muscle and waste products such as carbon dioxide are removed (Haghshenas et al., 2019). Many factors such as proteins could be associated with cardiovascular risk factors and other diseases (Doaei et al., 2018; Shidfar et al., 2018).

Amino acids are among the most common nutritional supplements which are used by athletes to improve athletic performance under aerobic and anaerobic conditions (Mashiko et al., 2004). L-arginine is one of the semi-essential amino acids that has positive effects on muscle metabolism (Preli et al., 2002). L-arginine may also have a key role in the cardiac function of athletes. Arginine is a precursor of nitric oxide (NO) and NO causes vasodilatory effects, increased blood flow to the muscles, and increased release of certain hormones such as insulin and human growth hormone (Adams et al., 1995; Moazami et al., 2015). Oral L-arginine supplements improved coronary endothelium-dependent dilation (Melik et al., 2017).

L-arginine may have led to delayed fatigue by altering blood lactate concentration and metabolic indices of respiration. It is frequently reported that using L-arginine supplement may improve athletic performance in sports activities. (Yaman et al., 2010). Yaman et al. found that L-arginine supplementation (LAS) significantly reduced blood pressure and increased VO₂ max and may influence athletic performance capacity (Kalman et al., 2016).

However, the studies on the association between LAS and VO₂ max reported contradictory results. Therefore, this systematic review and meta-analysis aimed to investigate the effect of LAS on VO₂ max.

2 | METHODS AND MATERIALS

2.1 | Literature search strategy

This systematic review and meta-analysis was performed in accordance with PRISMA (Preferred Reporting Items

for Systematic Reviews and Meta-Analyses) guidelines (Liberati et al., 2009). The scientific databases including PubMed, Scopus, Web of Science, Cochrane, Embase, ProQuest, and Ovid were reviewed to identify all relevant literature on the effects of LAS on VO₂ max that were published by August 2020. The following search strategy was used to finalize the first step of data gathering: (Arginine[Mesh] OR Arginine[tiab]) AND (VO₂[tiab] OR "maximal aerobic"[tiab] OR "aerobic capacity"[tiab] OR "maximal O₂"[tiab] OR "maximal O₂ consumption"[tiab] OR "maximal O₂ uptake"[tiab] OR "peak O₂"[tiab] OR "maximal oxygen consumption"[tiab] OR "maximal oxygen uptake"[tiab] OR "peak oxygen uptake"[tiab] OR "maximal aerobic capacity"[tiab]).

To enhance the quality of the searches, hand searching was performed to find all relevant articles using the references of the collected articles. The searches were limited to human studies and no language restriction was used in the search process. Two authors (Sh. R and P. N) independently screened the title and the abstracts of the included papers, performed data extraction, and carried out the quality assessments of the eligible studies. All disagreements were resolved by consulting with a third author (R. T).

2.2 | Study selection

The following strategy was used to select the eligible papers for performing the meta-analysis: Randomized clinical trials (parallel or cross-over) experiments, investigated the effect of LAS on VO₂ max in healthy human subjects, individuals supplemented with arginine were compared to placebo-control individuals, arginine supplementation administered for at least 1 week, papers with enough information to measure the VO₂ max, papers contained data for SD, SE, and CI parameters in the beginning and the end of the study for both of the intervention and control groups.

2.3 | Data extraction

All eligible randomized controlled trials were separately re-checked and the following data were extracted: the name of the first author, country, the number of individuals in the intervention and control groups, the form of supplemented arginine, arginine doses, duration of the study, type of the study, and the related data for further steps (Table 1). For each study, the value of mean and SD for VO₂ max in the beginning and at the end of the study was extracted. The following formula was used to calculate the mean difference of SDs:

TABLE 1 Participant and intervention characteristics of the studies included in the systematic review and meta-analysis

ID	Authors	Year	Country	Population	Age	Number of subjects in intervention/control groups	Type of study	Type of Intervention	Control group	Duration of study
1	Camic et al.	2010	USA	College-aged male	22.1 ± 2.4	21/20	Randomized, double-blind, placebo, controlled, parallel design	3 g/day, LAS+300 mg of grape seed extract + 300 mg of polyethylene glycol	Placebo	28 days
2	Chen et al.	2010	USA	Male cyclists	ARG:57.6 ± 4.6 PLA: 60.6 ± 8.7	8/8	Two-arm prospectively randomized double-blinded and placebo-controlled trial	5.2 g/day, LAS + L-citrulline + 500 mg ascorbic acid, 400 IU vitamin E, 400 µg folic acid, 300 mg L-tyrosine, and 10 mg alpha lipoic acid	Placebo	21 days
3	Muazzezaneh et al.	2010	Iran	Healthy athletes	22.66 ± 1.46	14/13	Based on a single-blind placebo-controlled trial	5 g/day, LAS	Placebo	21 days
4	Sunderland et al.	2011	USA	Endurance-trained male cyclists	36.3 ± 7.9	9/9	Randomized, conducted in a double-blind manner	12 g/day, LAS	Placebo	28 days
5	Moazami et al.	2014	Iran	Female handballists	2.49 ± 22.15	8/8	Randomized clinical trial	3 g/day, LAS	Placebo	7 days
6	Zak et al.	2015	USA	Untrained men	22.0 ± 1.7	19/19	Double blinded, placebo-controlled, within subjects' crossover design	3 g/day, LAS + 300 mg of grape seed extract (95% procyanidins), and 300 mg of polyethylene glycol	Placebo	7 days
7	Hosseini et al.	2015	Iran	Healthy futsal players	22.5 ± 1.39	10/10	Randomized control trial	4 g/day, LAS	Placebo	28 days
8	Pahlavani et al.	2017	Iran	Soccer players	20.85 ± 4.29	25/27	Double-blinded, randomized, placebo-controlled trial	2 g/day, LAS	Placebo	45 days
9	Dennis et al.	1991	France	Medical students, active in recreational activities	19–26	15/15	Double-blind, cross-over study	5 g/day, AA	Placebo	10 days
10	Burtscher et al.	2005	Austria	Healthy athletes	22 ± 3	8/8	Double blind placebo-controlled trial	3 g/day, AA	Placebo	21 days
11	Campbel et al.	2005	USA	Resistance-trained healthy adult men	38.9 ± 5.8	20/15	Randomized, double-blind, controlled design	12 g/day, AAKG	Placebo	56 days

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data addressed (attrition bias)	Selective reporting (reporting bias)	other sources of bias (e.g. bias of study design, trial stoppage early, extreme baseline imbalance, and fraudulent trial)
Burtscher (2005)	?	?	+	?	+	+	+
Camic (2010)	?	?	+	?	+	+	+
Campbel (2006)	?	?	+	?	+	+	+
Chen (2010)	?	?	+	+	+	+	+
Dennis (1991)	?	?	+	?	+	+	+
Hosseini (2015)	?	?	?	?	+	+	+
Moazami (2014)	?	?	+	?	+	+	+
Muazzezaneh (2010)	+	+	+	?	+	+	+
Pahlavani (2017)	+	+	+	?	+	+	+
Sunderland (2011)	?	?	+	?	+	+	+
Zak (2015)	?	?	+	?	+	+	+

FIGURE 1 Summary of risk of bias: According to Cochrane criteria, any source of bias including selection bias, performance bias, detection bias, attrition bias, and reporting bias were judged for all included studies

$$SD = \text{square root} \left[(SD \text{ at baseline})^2 + (SD \text{ at the end of study})^2 - (2R \times SD \text{ at baseline} \times SD \text{ at the end of study}) \right]$$

A correlation coefficient of 0.5 was used for *R*, estimated between 0 and 1 values, respectively. Also, the formula $SD = SE \times \sqrt{n}$ (*n* = the number of individuals in each group) was used to measure SD in each article that reported SE instead of SD.

2.4 | Quality assessment

The quality assessment of the included papers in this meta-analysis was performed according to Cochrane criteria (Higgins, 2011). According to this guideline, any source of bias including selection bias, performance bias, detection bias, attrition bias, and reporting bias were judged for all included studies (Figure 1).

2.5 | Statistical analysis

This meta-analysis was conducted using Stata version 11. Due to the population selection from different countries, a random-effects model was employed with a 95% confidence interval (CI) for the calculation of the pooled weighted mean difference (WMD). Analysis endpoints were calculated as the difference in mean between baseline and post-treatment (measure at the end of follow-up – measure at baseline); also, the SD of mean change was calculated by the pooled SD. The statistical heterogeneity between trials was calculated by p-value and using I² statistic (*p* < 0.05 and *I*² > 50%). Publication bias was checked by the funnel plot, Begg's test (*p* = 0.815), and Egger's tests (*p* = 0.218; Figure 2).




FIGURE 2 Publication bias was checked by the funnel plot, Begg's (*p* = 0.815) test, and Egger's (*p* = 0.218) tests. SE, standard error; WMD, weighted mean difference

3 | RESULTS

3.1 | Search results and study selection

The flow chart presented in Figure 3 describes the process of selection and the references retrieved in the database. A total number of 945 articles was identified in the first step of the literature search of electronic databases. After excluding duplicated studies ($n = 617$), irrelevant studies based on title and abstracts ($n = 295$), type of intervention ($n = 1$), type of outcomes ($n = 5$), and the required data ($n = 4$), 23 potentially relevant articles were considered for full text review. After screening, 12 articles were excluded for the following reasons: studies population, insufficient data reporting of outcome, and type of LAS. Finally, 11 studies were included in the present meta-analysis (Burtscher et al., 2005; Camic et al., 2010; Campbell et al., 2006; Chen et al., 2010; Denis et al., 1991; Hosseini et al., 2015; Moazami et al., 2015; Muazzezaneh et al., 2010; Pahlavani et al., 2017; Sunderland et al., 2011; Zak et al., 2015).

3.2 | Quantitative data synthesis

Marginal significant increase in VO_2 max (WMD = 0.07 L min^{-1} ; 95% CI, 0.00–0.13, $p = 0.047$;

$I^2 = 23.2\%$) was found after L- arginine supplementation in comparison with the control group (Figure 4).

3.3 | Subgroup analysis

Subgroup analysis was performed based on the study duration (≥ 14 days), dosage of L-arginine ($< 5 \text{ g/day}$), and the type of arginine supplementation including LAS, arginine aspartate, arginine alpha-Ketoglutarate, and arginine in combination with antioxidants to detect the source of heterogeneity. There was a significant increase in VO_2 max in the subgroup analysis of trials with LAS (WMD = 0.11 L min^{-1} , $I^2 = 0.0\%$, p for heterogeneity = 0.485; Table 2).

3.4 | Sensitivity analysis

The sensitivity analysis was performed using “one-study-removed” method to survey the impact of each study on the effect size. The results of sensitivity analysis identified the higher and lower pooled weight mean difference for VO_2 max (WMD = 0.1 L min^{-1} ; 95% CI 0.08, 0.13) after excluding the Burtscher et al. (2005) study and (WMD = 0.03 L.min^{-1} ; 95% CI 0.04, 0.1) after excluding Hosseini et al. (2015) study, respectively (Figure 5).




FIGURE 3 Preferred Reporting Items for Systematic Review and Meta-Analyses flow diagram




FIGURE 4 Forest plot comparing the effects of L-Arg supplementation on VO₂ max

Subgroup analysis for VO ₂ max					
Subgroup	No. of trials	WMD (95% CI)	Test for the overall effect	Test for heterogeneity	I ² (%)
Duration of study (days)					
>14 days	8	0.05 (-0.04, -0.13)	p = 0.261	p = 0.102	41.5
≤14 days	3	0.11 (-0.06, 0.28)	p = 0.188	p = 0.596	0.0
L-arginine dose (g/day)					
<5	6	0.07 (-0.03, 0.17)	p = 0.186	p = 0.047	55.4
≥5	5	0.03 (-0.11, -0.16)	p = 0.704	p = 0.969	0.0
Type of L-arginine					
LAS	5	0.11 (0.08, 0.14)	p = 0.000	p = 0.485	0.0
AA	2	-0.06 (-0.25, 0.12)	p = 0.506	p = 0.250	24.5
Other	4	0.01 (-0.14, 0.17)	p = 0.852	p = 0.956	0.0

Abbreviations: AA, arginine aspartate; AAKG, arginine alpha-Ketoglutarate; LAS, L-arginine supplementation.

4 | DISCUSSION

This is the first meta-analysis that evaluates the effect of LAS on VO₂ max in healthy human subjects. The results indicated that LAS resulted in a mean increase of 0.07 L min⁻¹ for VO₂ max compared with placebo (95% CI, 0.00–0.13). No significant heterogeneity was detected in this meta-analysis. The subgroup analysis indicated that supplementation with L-arginine alone significantly increased VO₂ max compared to the other types of arginine or combined with other metabolites or supplements.


Evidence suggest the relationship between LAS and improved exercise performance. L-arginine is reported to have a

TABLE 2 Subgroup analysis was performed based on the study duration, dosage of L-arginine, and the form of arginine supplementation

key role in creatine synthesis as well as in increase endogenous growth hormone (Campbell et al., 2004). L-arginine is also the substrate for nitric oxide synthesis that plays a role in the autoregulation of blood flow, myocyte differentiation, respiration, and glucose homeostasis in muscle (Stamler & Meissner, 2001). Although some studies have shown a positive effect of LAS on exercise performance, the results of the trials which assessed the effect of LAS on VO₂ max were inconsistent.

A positive effect of LAS on VO₂ max was identified in the present meta-analysis. This finding is generally in line with some of the individual studies selected for this review. Hosseini et al. (2015) reported that 4 g/day arginine

FIGURE 5 The sensitivity analysis was performed using the “one-study-removed” method to survey the impact of each study on the effect size



supplementation for 4 weeks could significantly increase VO₂ max and subsequently improved sports performance in athletes. Another study conducted by Moazami et al. (2015) reported that VO₂ max was significantly increased after a 7-day supplementation of L-arginine at the dose of 21 g/day in female athletes. In addition, a placebo-controlled trial (Pahlavani et al., 2017) indicated that the oral supplementation of L-arginine at the dose of 2 g/day for 45 days could increase VO₂ max. Conversely, Burtscher et al. (2005) found that 3 weeks of L-arginine-L-aspartate supplementation at the dose of 3 g/day resulted in lower oxygen consumption and reduced ventilation during submaximal cycle exercise. This may be explained by the difference in physiological functions at a maximum level of effort compared with a submaximal (Larsen et al., 2007). It seems that nitric oxide derived from L-arginine through competitive inhibition of oxygen use in the electron transport chain result in lower whole-body oxygen consumption at submaximal work (Burtscher et al., 2005; Larsen et al., 2007; Schweizer & Richter, 1994).

However, some studies did not observe any significant association between the intake of LAS and VO₂ max (Abel et al., 2005; Zak et al., 2015). These inconsistent results may be explained by the different test protocols applied, study duration, dosages of L-arginine, form of L-arginine supplement, and also the level of physical fitness. For example, oral supplementation of L-arginine was used in combination with various other metabolites/salts in several studies that may cause synergistic or antagonistic effects (McConnell, 2007). Furthermore, the training status of the subjects seems to be an important factor related to the positive effect of LAS. LAS could have lower positive effects in well-trained participants comparing with untrained people (Besco et al., 2012). Moreover, different L-arginine dosages used in chronic and acute supplementation protocols could have different physiological mechanisms of action. A recent meta-analysis reported that the effective dose of LAS should be adjusted to 0.15 g/kg body weight taken 60–90 min before exercise in the acute protocol or 10–12 g LAS for 8 weeks in

chronic protocol for improving both aerobic and anaerobic performances (Viribay et al., 2020).

L-arginine can improve exercise performance by enhancing protein synthesis and reducing muscle fiber damage (Lomonosova et al., 2014). It is also the precursor of nitric oxide that is used to increase endurance and improvement in blood flow (Alvares et al., 2011; Moncada & Higgs, 1993). One of the possible mechanisms to describe the increase in VO₂ max is the nitric oxide derived from L-arginine that results in vessel vasodilatation and flow, which, in turn, may positively influence coronary perfusion. An increase in NO production may enhance oxygen and nutrients delivery to the active muscles. Therefore, oxygen consumption increases dramatically in the active muscles with a parallel increase in muscle blood flow. (Burgomaster et al., 2006; Nagaya et al., 2001; Stamler & Meissner, 2001).

The oral LAS also facilitates the phase II pulmonary VO₂ response. The proposed mechanism to explain this effect is an increase in L-arginine availability, with subsequent increases in certain tricarboxylic acid cycle intermediates which finally lead to enhance the oxidative metabolism (Koppo et al., 2009). However, further studies are needed to understand the exact mechanisms of how L-arginine affects VO₂ max in healthy human subjects.

Although this is the first meta-analysis that evaluates the effect of LAS on VO₂ max in healthy human subjects, it has some limitations. There were some differences in the supplementation protocols, doses, timing, and also form of L-arginine in the included trials which limited the extraction of strong conclusions.

5 | CONCLUSIONS

This meta-analysis indicated that LAS had a positive effect on increasing VO₂ max. Future homogeneous and well-designed randomized clinical trials are needed to a deep understand of the effects of L-arginine on VO₂ max in healthy human subjects.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

This study has been approved by Local ethics review boards at Shahid Beheshti University of Medical Sciences.

CONSENT FOR PUBLICATION

Institutional consent forms were used in this study.

ACKNOWLEDGMENTS

This study was conducted at the Student research center of Shahid Beheshti University of Medical Sciences, Tehran, Iran (code 13172).

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

AUTHORS' CONTRIBUTIONS

Maryam Gholamalizadeh, Saeid Doaei, and Shahla Rezaei designed the study, and were involved in the data collection, analysis, and drafting of the manuscript. Reza Tabrizi, Peyman Nowrouzi-Sohrabi, and Samira Rastgoo were involved in the design of the study, analysis of the data, and critically reviewed the manuscript. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT

Not applicable.

ORCID

Saeid Doaei  <https://orcid.org/0000-0002-2532-7478>

REFERENCES

- Abel, T., Knechtle, B., Perret, C., Eser, P., Von Arx, P., & Knecht, H. (2005). Influence of chronic supplementation of arginine aspartate in endurance athletes on performance and substrate metabolism. *International Journal of Sports Medicine*, 26(05), 344–349. <https://doi.org/10.1055/s-2004-821111>
- Adams, M. R., Forsyth, C. J., Jessup, W., Robinson, J., & Celermajer, D. S. (1995). Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. *Journal of the American College of Cardiology*, 26(4), 1054–1061. [https://doi.org/10.1016/0735-1097\(95\)00257-9](https://doi.org/10.1016/0735-1097(95)00257-9)
- Alvares, T. S., Meirelles, C. M., Bhambhani, Y. N., Paschoalin, V. M., & Gomes, P. S. (2011). L-Arginine as a potential ergogenic aid in healthy subjects. *Sports Medicine*, 41(3), 233–248. <https://doi.org/10.2165/11538590-000000000-00000>
- Besco, R., Sureda, A., Tur, J. A., & Pons, A. (2012). The effect of nitric-oxide-related supplements on human performance. *Sports Medicine*, 42(2), 99–117. <https://doi.org/10.2165/11596860-000000000-00000>
- Burgomaster, K. A., Heigenhauser, G. J., & Gibala, M. J. (2006). Effect of short-term sprint interval training on human skeletal muscle carbohydrate metabolism during exercise and time-trial performance. *Journal of Applied Physiology*, 100(6), 2041–2047. <https://doi.org/10.1152/jappphysiol.01220.2005>
- Burtscher, M., Brunner, F., Faulhaber, M., Hotter, B., & Likar, R. (2005). The prolonged intake of L-arginine-L-aspartate reduces blood lactate accumulation and oxygen consumption during submaximal exercise. *Journal of Sports Science & Medicine*, 4(3), 314.
- Camic, C. L., Housh, T. J., Mielke, M., Zuniga, J. M., Hendrix, C. R., Johnson, G. O., Schmidt, R. J., & Housh, D. J. (2010). The effects of 4 weeks of an arginine-based supplement on the gas exchange threshold and peak oxygen uptake. *Applied Physiology, Nutrition, and Metabolism*, 35(3), 286–293. <https://doi.org/10.1139/H10-019>
- Campbell, B. I., La Bounty, P. M., & Roberts, M. (2004). The ergogenic potential of arginine. *Journal of the International Society of Sports Nutrition*, 1(2), 1–4. <https://doi.org/10.1186/1550-2783-1-2-35>
- Campbell, B., Roberts, M., Kerksick, C., Wilborn, C., Marcello, B., Taylor, L., Nassar, E., Leutholtz, B., Bowden, R., Rasmussen, C., Greenwood, M., & Kreider, R. (2006). Pharmacokinetics, safety, and effects on exercise performance of L-arginine α -ketoglutarate in trained adult men. *Nutrition*, 22(9), 872–881. <https://doi.org/10.1016/j.nut.2006.06.003>
- Chen, S., Kim, W., Henning, S. M., Carpenter, C. L., & Li, Z. (2010). Arginine and antioxidant supplement on performance in elderly male cyclists: A randomized controlled trial. *Journal of the International Society of Sports Nutrition*, 7(1), 13. <https://doi.org/10.1186/1550-2783-7-13>
- Denis, C., Dormois, D., Linossier, M., Eychenne, J., Hauseux, P., & Lacour, J. (1991). Effect of arginine aspartate on the exercise-induced hyperammonemia in humans: a two periods cross-over trial. *Archives Internationales de Physiologie, de Biochimie et de Biophysique*, 99(1), 123–127. <https://doi.org/10.3109/13813459109145914>
- Doaei, S., Hajjesmaeil, M., Aminifard, A., Mosavi-Jarrahi, S., Akbari, M., & Gholamalizadeh, M. (2018). Effects of gene polymorphisms of metabolic enzymes on the association between red and processed meat consumption and the development of colon cancer: a literature review. *Journal of Nutritional Science*, 7. <https://doi.org/10.1017/jns.2018.17>
- Epstein, F. H., Moncada, S., & Higgs, A. (1993). The L-arginine-nitric oxide pathway. *New England Journal of Medicine*, 329(27), 2002–2012. <https://doi.org/10.1056/NEJM199312303292706>
- Gutin, B., Yin, Z., Humphries, M. C., & Barbeau, P. (2005). Relations of moderate and vigorous physical activity to fitness and fatness in adolescents. *The American Journal of Clinical Nutrition*, 81(4), 746–750. <https://doi.org/10.1093/ajcn/81.4.746>
- Haghshenas, R., Jamshidi, Z., Doaei, S., & Gholamalizadeh, M. (2019). The effect of a high-intensity interval training on plasma vitamin D level in obese male adolescents. *Indian Journal of Endocrinology and Metabolism*, 23(1), 72–75. https://doi.org/10.4103/ijem.IJEM_267_18
- Higgins, J. (2011). Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. Retrieved from www.cochrane-handbook.org
- Hosseini, A., & Valipour Dehno, V., Azizi, M., & Khanjari Alam, M. (2015). Effect of high-intensity interval training (HIT) for 4 weeks with and without L-arginine supplementation on the performance of women's futsal players. *Quarterly of Horizon of Medical Sciences*, 21(2), 113–119. <https://doi.org/10.18869/acadpub.hms.21.2.113>
- Kalman, D., Harvey, P. D., Perez Ojalvo, S., & Komorowski, J. (2016). Randomized prospective double-blind studies to evaluate the

- cognitive effects of inositol-stabilized arginine silicate in healthy physically active adults. *Nutrients*, 8(11), 736. <https://doi.org/10.3390/nu8110736>
- Koppo, K., Taes, Y. E., Pottier, A., Boone, J., Bouckaert, J., & Derave, W. (2009). Dietary arginine supplementation speeds pulmonary VO₂ kinetics during cycle exercise. *Medicine & Science in Sports & Exercise*, 41(8), 1626–1632. <https://doi.org/10.1249/MSS.0b013e31819d81b6>
- Larsen, F., Weitzberg, E., Lundberg, J., & Ekblom, B. (2007). Effects of dietary nitrate on oxygen cost during exercise. *Acta Physiologica*, 191(1), 59–66. <https://doi.org/10.1111/j.1748-1716.2007.01713.x>
- Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. *Journal of Clinical Epidemiology*, 62(10), e1–e34. <https://doi.org/10.1016/j.jclinepi.2009.06.006>
- Lomonosova, Y. N., Shenkman, B. S., Kalamkarov, G. R., Kostrominova, T. Y., & Nemirovskaya, T. L. (2014). L-arginine supplementation protects exercise performance and structural integrity of muscle fibers after a single bout of eccentric exercise in rats. *PLoS One*, 9(4), e94448. <https://doi.org/10.1371/journal.pone.0094448>
- Mashiko, T., Umeda, T., Nakaji, S., & Sugawara, K. (2004). Position related analysis of the appearance of and relationship between post-match physical and mental fatigue in university rugby football players. *British Journal of Sports Medicine*, 38(5), 617–621. <https://doi.org/10.1136/bjism.2003.007690>
- McConell, G. K. (2007). Effects of L-arginine supplementation on exercise metabolism. *Current Opinion in Clinical Nutrition and Metabolic Care*, 10(1), 46–51. <https://doi.org/10.1097/MCO.0b013e32801162fa>
- Melik, Z., Zaletel, P., Virtic, T., & Cankar, K. (2017). L-arginine as dietary supplement for improving microvascular function. *Clinical Hemorheology and Microcirculation*, 65(3), 205–217.
- Moazami, M., Taghizadeh, V., Ketabdar, A., Dehbashi, M., & Jalilpour, R. (2015). Effects of oral L-arginine supplementation for a week, on changes in respiratory gases and blood lactate in female handballists. *Iranian Journal of Nutrition Sciences & Food Technology*, 9(4), 45–52.
- Muazzezaneh, A., Keshavarz, S. A., Sabour Yaraghi, A. A., Djalali, M., & Rahimi, A. (2010). Effect of L-arginine supplementation on blood lactate level and VO₂ max at anaerobic threshold performance. *KAUMS Journal (FEYZ)*, 14(3), 200–208.
- Nagaya, N., Uematsu, M., Oya, H., Sato, N., Sakamaki, F., Kyotani, S., Ueno, K., Nakanishi, N., Yamagishi, M., & Miyatake, K. (2001). Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, 163(4), 887–891. <https://doi.org/10.1164/ajrccm.163.4.2007116>
- Pahlavani, N., Entezari, M., Nasiri, M., Miri, A., Rezaie, M., Bagheri-Bidakhavidi, M., & Sadeghi, O. (2017). The effect of l-arginine supplementation on body composition and performance in male athletes: A double-blinded randomized clinical trial. *European Journal of Clinical Nutrition*, 71(4), 544–548. <https://doi.org/10.1038/ejcn.2016.266>
- Prelj, R. B., Klein, K. P., & Herrington, D. M. (2002). Vascular effects of dietary L-arginine supplementation. *Atherosclerosis*, 162(1), 1–15. [https://doi.org/10.1016/S0021-9150\(01\)00717-1](https://doi.org/10.1016/S0021-9150(01)00717-1)
- Ruiz, J. R., Rizzo, N. S., Hurtig-Wennlöf, A., Ortega, F. B., Wärnberg, J., & Sjöström, M. (2006). Relations of total physical activity and intensity to fitness and fatness in children: The European Youth Heart Study. *The American Journal of Clinical Nutrition*, 84(2), 299–303. <https://doi.org/10.1093/ajcn/84.2.299>
- Schweizer, M., & Richter, C. (1994). Nitric oxide potently and reversibly deenergizes mitochondria at low oxygen tension. *Biochemical and Biophysical Research Communications*, 204(1), 169–175. <https://doi.org/10.1006/bbrc.1994.2441>
- Shidfar, F., Bahrololumi, S. S., Doaei, S., Mohammadzadeh, A., Gholamalazadeh, M., & Mohammadimanesh, A. (2018). The effects of extra virgin olive oil on alanine aminotransferase, aspartate aminotransferase, and ultrasonographic indices of hepatic steatosis in nonalcoholic fatty liver disease patients undergoing low calorie diet. *Canadian Journal of Gastroenterology and Hepatology*, 2018, 1–7. <https://doi.org/10.1155/2018/1053710>
- Stamler, J. S., & Meissner, G. (2001). Physiology of nitric oxide in skeletal muscle. *Physiological Reviews*, 81(1), 209–237. <https://doi.org/10.1152/physrev.2001.81.1.209>
- Sunderland, K. L., Greer, F., & Morales, J. (2011). JOURNAL/jscr/04.02/00124278-201103000-00034/ENTITY_OV0312/v/2017-07-20T235437Z/t/image-pngo2max and ventilatory threshold of trained cyclists are not affected by 28-day L-arginine supplementation. *The Journal of Strength and Conditioning Research*, 25(3), 833–837. <https://doi.org/10.1519/jsc.0b013e3181c6a14d>
- Viribay, A., Burgos, J., Fernández-Landa, J., Seco-Calvo, J., & Mielgo-Ayuso, J. (2020). Effects of arginine supplementation on athletic performance based on energy metabolism: A systematic review and meta-analysis. *Nutrients*, 12(5), 1300.
- Yaman, H., Tiryaki-Sönmez, G., & Gürel, K. (2010). Effects of oral L-arginine supplementation on vasodilation and VO₂ max in male soccer players. *Biomedical Human Kinetics*, 2(1), 25–29. <https://doi.org/10.2478/v10101-010-0006-x>
- Zak, R. B., Camic, C. L., Hill, E. C., Monaghan, M. M., Kovacs, A. J., & Wright, G. A. (2015). Acute effects of an arginine-based supplement on neuromuscular, ventilatory, and metabolic fatigue thresholds during cycle ergometry. *Applied Physiology, Nutrition, and Metabolism*, 40(4), 379–385. <https://doi.org/10.1139/apnm-2014-0379>

How to cite this article: Rezaei S, Gholamalazadeh M, Tabrizi R, Nowrouzi-Sohrabi P, Rastgoo S, Doaei S. The effect of L-arginine supplementation on maximal oxygen uptake: A systematic review and meta-analysis. *Physiol Rep*. 2021;9:e14739. <https://doi.org/10.14814/phy2.14739>